The drug formularies of public health care programs should favor American-made drugs, according to Coherus BioSciences, and the biosimilars maker is pitching this new idea as a way to protect the U.S. drug supply chain and boost U.S. manufacturing. “If there is an American-made pharmaceutical product available, it should be preferred and paid for with that in mind so that jobs and U.S. tax dollars are not sent overseas unnecessarily,” Coherus states in a March 26 letter to the administration...